Age-dependent pharmacokinetics of lansoprazole in neonates and infants

Pediatric Drugs

Volumn 10, Issue 4, 2008, Pages 265-274

  Zhang, Weijiang ^a   Kukulka, Michael ^a   Witt, Galen ^a   Sutkowski Markmann, Debra ^a   North, Janine ^a   Atkinson, Stuart ^a  

^a TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

Infants; Lansoprazole, pharmacokinetics; Neonates

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; PREVACID SOLUTAB;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GENOTYPE; HUMAN; INFANT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS PNEUMONIA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGE FACTORS; ANTI-ULCER AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROESOPHAGEAL REFLUX; HALF-LIFE; HUMANS; INFANT; INFANT, NEWBORN; MALE; POLYMORPHISM, GENETIC;

EID: 46349101067     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810040-00005     Document Type: Article

References (30)

1. Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32 Suppl. 2: S1-31
2. Gold BD. Review article: epidemiology and management of gastro-oesophageal reflux in children. Aliment Pharmacol Ther 2004; 19 Suppl. 1: 22-7
3. Cezard JP. Managing gastro-oesophageal reflux disease in children. Digestion 2004; 69 Suppl. 1: S3-8
4. Miyazawa R, Tomomasa T, Kaneko H, et al. Prevalence of gastro-esophageal reflux-related symptoms in Japanese children. Pediatr Int 2002; 44 (5): 513-6
5. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastro-esophageal reflux during infancy: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997; 151 (6): 569-72
6. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94 (6): 1434-42
7. Rerksuppaphol S, Barnes G. Guidelines for evaluation and treatment of gastro-esophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2002; 35 (4): 583
8. DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100 (1): 190-200
9. Prevacid delayed-release capsules, delayed-release oral suspension, and delayed-release orally disintegrating tables [package insert]. Lake Forest (IL): TAP Pharmaceutical Products Inc., 2004 Jul
10. Gremse D, Winter H, Tolia V, et al. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002; 35 Suppl. 4: S319-26
11. Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001; 15 (9): 1397-402
12. Tran A, Rey E, Pons G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002; 71 (5): 359-67
13. Gunasekaran T, Gupta S, Gremse D, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy and tolerability. J Pediatr Gastroenterol Nutr 2002; 35: S327-35
14. Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005; 44 (5): 441-66
15. Tolman KG, Sanders SW, Buchi KN, et al. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65-70
16. Jadcherla SR. Gastroesophageal reflux in the neonate. Clin Perinatol 2002; 29: 135-53
17. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209
18. Andersson T, Holmberg J, Rohss K, et al. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole and pantoprazole. Br J Clin Pharmacol 1998; 45: 369-75
19. Sakai T, Aoyama N, Kita T, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 18: 721-7
20. Kim KA, Shon JH, Park JY, et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin Pharmacol Ther 2002; 72: 90-9
21. Springer M, Atkinson S, North J, et al. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year. Pediatr Drugs 2008; 10 (4): 255-63
22. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, 1964 and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 [online]. Available from URL: http://www.wma.net/e/policy/b3.htm [Accessed 2008 Jun 3]
23. Katsuki H, Hamada A, Makamura C, et al. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol 2001; 57: 709-15
24. Andersson T, Gothberg G, Friberg L, et al. Pharmacokinetics of intravenous omeprazole in neonates and infants [abstract]. J Pediatr Gastroenterol Nutr 2001; 33: 424
25. Andersson T, Anderson G, Dasen S, et al. Pharmacokinetics and pharmacodynamics of oral omeprazole in infants. [abstract]. J Pediatr Gastroenterol Nutr 2001; 33: 424
26. Kearns GL, Andersson T, James LP, et al. Omeprazole disposition in children following single-dose administration. J Clin Pharmacol 2003; 43: 840-8
27. Bartelink IH, Rademaker CM, Schobben AF, et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45 (11): 1077-97
28. Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625-34
29. Treluyer JM, Gueret G, Cheron G, et al. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in vitro correlation and inducibility. Pharmacogenetics 1997; 7: 441-52
30. Treluyer JM, Cheron G, Sonnier M, et al. Cytochrome P450 expression in sudden infant death syndrome. Biochem Pharmacol 1996; 52: 497-504